CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESS
SHARE THIS ARTICLE
Leading heart failure specialist features tecarfarin data and Cadrenal's proposed clinical trial protocol at 8th EACTS Mechanical Circulatory Support Summit
ONTE VEDRA, Fla., Nov. 12, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) anticoagulant, today highlighted a key opinion leader presentation at the November 2024 European Association for Cardio-thoracic Surgery (EACTS) Mechanical Circulatory Support Summit that featured tecarfarin historical data and Cadrenal's proposed clinical trial protocol to evaluate tecarfarin versus warfarin in patients with the Abbott HeartMate3 (HM3) left ventricular assist device (LVAD).
The presentation, titled Tecarfarin and Hemocompatibility with LVAD Therapy (TECH-LVAD), took place in Prague, Czech Republic and outlined Cadrenal's proposed clinical trial protocol recently submitted to the U.S. Food and Drug (FDA). Dr. Mandeep R. Mehra, who holds the William Harvey Chair in Advanced Cardiovascular Medicine and is Executive Director, Center for Advanced Heart Disease, Brigham and Women's Hospital, developed and delivered the TECH-LVAD presentation. In the presentation Dr. Mehra highlighted data from past trials demonstrating the inverse relationship between bleeding rates and time in therapeutic range (TTR) for HM3 patients, and evidence from prior studies indicating tecarfarin's potential ability to improve TTR. He included data from a trial in end-stage kidney disease (ESKD) patients showing that ESKD does not alter tecarfarin exposure while warfarin exposure is increased, explaining that this is one of the critical differentiators for tecarfarin because many LVAD patients have kidney impairment.
Dr. Mehra, who also chaired Abbott's ARIES-HM3 study in LVAD patients and is a Professor of Medicine, Harvard University, commented, "In the proposed TECH-LVAD trial, we plan to study a much-needed VKA option with the expectation of reducing bleeding events that accompany use of the HM3 LVAD in advanced heart failure. Tecarfarin could potentially be an important therapy for patients with LVADs who all require chronic anticoagulation."
"As our team progresses discussions with the FDA and Abbott about a tecarfarin study in LVAD patients, increasing tecarfarin data visibility will help us to continue accelerating our development as we plan for investigator outreach and patient recruitment for our tecarfarin trial," said Quang X. Pham, Chief Executive Officer of Cadrenal Therapeutics.
ABOUT CADRENAL THERAPEUTICS, INC.
Cadrenal Therapeutics is a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) designed to offer safer, more effective chronic anticoagulation for patients with implanted cardiac devices or rare cardiovascular conditions. Tecarfarin is anticipated to result in fewer adverse events such as strokes, heart attacks, bleeds, and deaths than warfarin, the most commonly used anticoagulant for these patients, despite its prevalent adverse events, drug-to-drug interactions, and frequent dosing changes. Cadrenal is focused on evaluating tecarfarin's superiority to warfarin in these patients where direct oral anticoagulants (DOACs) are not recommended in the treatment guidelines of leading cardiology associations. Tecarfarin received an orphan drug designation for advanced heart failure patients with implanted left ventricular assist devices (LVADs) as well as both orphan drug and fast-track status for end-stage kidney disease patients with atrial fibrillation. Cadrenal is opportunistically planning pivotal clinical trials and pursuing clinical and commercial partnerships to advance tecarfarin. The company's plans also include studying tecarfarin in patients with mechanical heart valves experiencing anticoagulation difficulties. Visit www.cadrenal.com to learn more.
Safe Harbor Statement
Any statements contained in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include statements regarding our planned pivotal trial to evaluate tecarfarin's effectiveness for LVAD patients, tecarfarin's potential ability to improve TTR; the plan to study a much-needed VKA option with the expectation to reduce bleeding events that accompany use of the HM3 LVAD in advanced heart failure; tecarfarin potentially being an important therapy for patients with LVADs who all require chronic anticoagulation and advancing the visibility of tecarfarin data helping to continue to accelerate the Company's development as it plans for investigator outreach and patient recruitment for its tecarfarin trial. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the ability of tecarfarin to improve TTR and anticoagulation treatment in patients, the ability of the Company to advance tecarfarin with patients with left ventricular assist devices (LVADs) and those with ESKD with AFib, the collaborative efforts with Abbott being successful and the other risk factors described in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, and the Company's subsequent filings with the Securities and Exchange Commission, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.
For more information, please contact:
SOURCE Cadrenal Therapeutics, Inc.
MASTER LEGAL DISCLAIMER
Effective Date: August 2024
Last Updated: May 17, 2025
Publisher: Relqo Media LLC (Wyoming, United States)
Subject Company: Cadrenal Therapeutics, Inc. (CVKD)
IMPORTANT SUMMARY — PLEASE READ FIRST
This website and any affiliated digital materials are published by Relqo Media LLC, a Wyoming marketing agency that has been compensated in cash by Genesis One Holdings LLC to produce and distribute promotional content regarding Cadrenal Therapeutics, Inc. (NASDAQ: CVKD). This communication is a paid advertisement, not a research report, not investment advice, and not an independent publication. Relqo Media is not a broker-dealer, investment adviser, or securities analyst. Investing in small-cap or microcap securities is extremely speculative and may result in the total loss of your investment. We strongly urge all viewers to consult a licensed investment professional and perform their own due diligence.
1. NATURE AND INTENT OF THIS COMMUNICATION
Relqo Media LLC is a for-profit marketing agency engaged in paid promotions of public companies. The content we produce is strictly commercial and intended to create temporary public awareness, visibility, and short-term market activity around the featured company. This material is not impartial. All readers should interpret our content as a paid commercial advertisement and not as an editorial, research article, or independent commentary. We create advertisements, not analysis. These Communications are not intended to be factual evaluations of the company’s operations or investment merit.
2. COMPENSATION FOR CADRENAL THERAPEUTICS, INC. (CVKD)
Relqo Media LLC has been retained by Genesis One Holdings LLC to provide promotional media services for Cadrenal Therapeutics, Inc. (NASDAQ: CVKD). As of the effective date:
- Relqo Media LLC is receiving cash compensation for digital investor awareness campaigns.
- The total compensation paid for these services is $25,000 per week, paid weekly, for the period beginning January 1, 2025 through July 1, 2025, totaling $650,000.
- Genesis One Holdings LLC may own, acquire, or dispose of shares in CVKD during or after the campaign period.
This relationship creates a material conflict of interest. Relqo Media’s content regarding CVKD should be considered promotional, biased, and financially motivated.
3. INTENDED AUDIENCE
These Communications are directed solely to U.S.-based, self-directed investors who understand the risks of investing in microcap and Nasdaq-listed securities. The content is not intended for children, seniors, retirement accounts, or individuals with limited experience in securities trading. These Communications are not intended to guide investment for long-term portfolio management or financial planning purposes.
4. NO ENDORSEMENT OR VERIFICATION OF COMPANY CLAIMS
Relqo Media LLC does not independently verify, investigate, or audit any statements made by the company being promoted, its officers, its press releases, or any third-party sources. Any claims, projections, customer announcements, or product statements made in connection with CVKD should be assumed to be unverified and potentially inaccurate unless independently confirmed. You should not rely on any statements regarding future performance, partnerships, revenue projections, or corporate plans.
5. MARKET INFLUENCE AND TRADING PATTERN EXPECTATION
Promotional campaigns commonly result in short-lived spikes in stock price and volume, followed by rapid declines. These spikes are typically driven by retail speculation, promotional circulation, and momentary investor interest—not fundamentals. You should expect that:
- CVKD’s stock may increase temporarily during this promotion,
- Trading volume may rise sharply, and
- The price may fall after the campaign ends or selling begins.
These patterns are typical of stock promotions, and you should proceed accordingly.
6. NO RELIANCE – INVESTOR RESPONSIBILITY
The burden of research, investigation, and risk assessment rests solely with you. Relqo Media LLC is not responsible for your investment decisions. You are strongly urged to:
- Read public filings from the SEC,
- Consult a licensed financial adviser,
- Understand risks such as dilution, insider selling, and volatility, and
- Recognize that speculative stocks often lack financial transparency.
We accept no responsibility for losses incurred due to actions taken based on our Communications.
7. FORWARD-LOOKING STATEMENTS AND SAFE HARBOR
Our materials may include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These include statements about potential growth, revenue forecasts, market opportunity, strategic partnerships, or technological development. Such statements are speculative and based on assumptions that may never occur. Actual results may differ materially. These statements are made under the safe harbor protections of Sections 27A and 21E of the Securities Acts. Relqo Media disclaims any duty to update them.
8. INFORMATION SOURCING, BIAS, AND ACCURACY
We use publicly available information including company websites, press releases, and promotional materials supplied by paying clients or related parties. We do not verify or validate this data.
Assume all information presented by Relqo Media is:
- Subjective,
- Not independently verified,
- Created to highlight potential upside and omit downsides,
- Not suitable as the basis for any investment decision.
9. OWNERSHIP AND TRADING CONFLICTS
Relqo Media LLC, its contractors, members, and affiliates may hold or acquire shares in the companies we promote, including CVKD. We may buy or sell such shares without prior notice. These transactions may occur before, during, or after a promotional campaign and may affect market pricing. We are not obligated to update readers on our trading activity or affiliate holdings.
10. MARKETING TOOLS, DATA COLLECTION, AND USER CONSENT
We use a range of outreach and promotional tools, including:
- Email and newsletter distributions,
- SMS/MMS text campaigns,
- Social media posts and influencers,
- Google and native display ads,
- Press releases, video marketing, and paid content distribution.
By engaging with our content, you consent to receive ongoing marketing communications. You may unsubscribe, but your data may be retained for audit or compliance purposes. Please refer to our Privacy Policy for further details.
11. ADVERTISING LAW COMPLIANCE
Relqo Media LLC produces promotional content in accordance with the advertising disclosure standards set forth by the Federal Trade Commission (FTC) and the SEC’s interpretations of sponsored investment-related communications.
We make good-faith efforts to disclose all:
- Compensation arrangements,
- Conflicts of interest,
- Risks,
- Limitations of our role, and
- The promotional nature of this content.
We do not provide investment recommendations under any regulatory framework including, but not limited to, SEC Regulation Analyst Certification, FINRA Rule 2210, or Regulation Best Interest.
12. NON-U.S. USERS
This material is intended solely for distribution within the United States. If you are accessing this site from outside the U.S., you are responsible for complying with your country’s laws. Relqo Media disclaims liability for access from non-U.S. jurisdictions where investor promotion, marketing, or solicitation of securities is restricted or prohibited.
13. DISCLAIMER OF WARRANTIES AND LIMITATION OF LIABILITY
All content is provided “as-is” and without warranties of any kind, either express or implied. Relqo Media LLC disclaims any and all liability for:
- Investment losses,
- Inaccuracies,
- Technical delays,
- User misunderstandings,
- Omissions or errors in content.
Total liability for any claim shall not exceed one hundred dollars ($100).
14. LEGAL GOVERNANCE AND DISPUTE RESOLUTION
All matters arising out of this disclaimer shall be governed by the laws of the State of Wyoming. You agree that any dispute shall be resolved exclusively through binding arbitration under the rules of the American Arbitration Association, to be held in Sheridan County, Wyoming. Class action claims and group arbitration are expressly prohibited.
15. NON-SOLICITATION AND GEOGRAPHIC LIMITATIONS
Nothing in our content constitutes a general solicitation or a personal securities recommendation. If you reside in a jurisdiction where such communications are unlawful, you must exit this site and discontinue engagement with our content.
16. FINAL NOTICE – ACCEPTANCE OF TERMS
We reserve the right to update this Disclaimer at any time without notice. Your continued use of our services or content constitutes acceptance of the most recent version.
If you do not accept all terms of this disclaimer in full, you must:
- Exit our websites,
- Unsubscribe from our communications,
- Discontinue viewing all Relqo Media promotional content.
17. NO RELIANCE
By viewing or engaging with this content, you agree that:
- You will not rely on any statements made by Relqo Media for investment purposes,
- You waive any claim that our content was a material factor in your investment decision,
- You have read, understood, and accepted this disclaimer in full.
© 2024 Relqo Media LLC. All Rights Reserved.
Legal Contact: 📧 support@stockverse.com
Mailing Address: 1309 Coffeen Ave Ste 1200, Sheridan, WY 82801
Affiliate Disclosure: Relqo Media LLC owns and operates Stockverse.com and all affiliated digital properties.